Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH011 in Recurrent High-Risk NMIBC After BCG Failure
NCT06732531Phase 2Recruiting
- Sponsor
- Zhuhai Beihai Biotech
- Start
- Aug 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BH011 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Zhuhai Beihai Biotech. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Complete Response Rate at 3 months. Started Aug 2022; status: recruiting.
02
Drugs
BH011
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06732531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732531.